Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Aileron Therapeutics, Inc.

Clinical trials sponsored by Aileron Therapeutics, Inc., explained in plain language.

Now part of Rein Therapeutics, Inc. RNTX NASDAQ

A clinical-stage biopharmaceutical company developing peptide therapeutics for cancer and other diseases.

Trade on eToro (ad)

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

New drug shows promise for Hard-to-Treat cancers with p53 gene

Disease control Completed

This study tested a new drug called ALRN-6924 in 142 people with advanced solid tumors or lymphomas that have a normal p53 gene. The goal was to see if the drug is safe and can shrink tumors. Participants had cancers that did not respond to standard treatments or had no standard …

Phase: PHASE1, PHASE2 • Sponsor: Aileron Therapeutics, Inc. • Aim: Disease control

Last updated Jun 27, 2026 08:10 UTC